Search

Existing literature has focused on the influence of organizational settings on volunteers' intention to remain but failed to explore the effects of external feedback. From an integrated perspective of task design and feedback, this study, based on the affective events theory, explored the influencing mechanism of illegitimate tasks, recipients' feedback, and emotional exhaustion on volunteers' intention to remain. This study collected 649 cases from poverty alleviation volunteers. Results showed that illegitimate tasks have had a negative impact on their intention to remain with emotional exhaustion taking a certain mediating effect. It has also been noted that the moderating effect of recipients' feedback is significant, which can alleviate the negative impact of emotional exhaustion on the intention to remain. This study indicated the positive effects of positive and negative feedback, enriched the research on the influencing factors of volunteers' intention to remain, and provided suggestions for organizations to retain volunteers from an integrated perspective of task design and feedback. [ABSTRACT FROM AUTHOR]

Purpose: Probing efficacy and safety of lusutrombopag in Chinese chronic liver disease (CLD) and severe thrombocytopenia (PLT < 50 × 109/L) patients undergoing elective invasive procedures. Methods: In this double-blind, parallel-group phase 3 study, 66 patients with CLD and severe thrombocytopenia were randomized 2:1 to lusutrombopag or placebo arm treatment regimens for seven days at 9 centers in China. Responders (PLT ≥ 50 × 109/L that increased to ≥ 20 × 109/L from the baseline and not received rescue therapy for bleeding) on Day 8 (the day after seven-day treatment) were assessed. PLT ≥ 50 × 109/L on or after Day 8 and within 2 days before invasive procedure (alternative criteria for not requiring platelet transfusion) were also analyzed. Adverse events (AEs) were recorded. Results: The proportion of responders on Day 8 was evidently higher (p = 0.0011) in the lusutrombopag group (43.2%, 19/44) versus placebo (4.5%, 1/22). And 72.7% (32/44) patients receiving lusutrombopag met the alternative criteria for not requiring platelet transfusion, while 18.2% (4/22) in the placebo group. The median maximum PLT in lusutrombopag group increased to 80.5 × 109/L, and median time to reach maximum was 14.5 days. Compared with placebo, the lusutrombopag group had a lower incidence of bleeding events (6.8% versus 13.6%), and only one patient had thrombotic-related AE. Overall, the incidence of treatment-emergent AEs was comparable between two groups. Conclusions: Lusutrombopag was effective in raising PLT, diminishing platelet transfusion requirement, and documented a safety profile like the placebo in CLD and severe thrombocytopenia patients in a Chinese cohort undergoing elective invasive procedures. Chinese clinical trial registration number: CTR20192384. [ABSTRACT FROM AUTHOR]